Grupo J Uriach S.L.
http://www.uriach.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grupo J Uriach S.L.
Innoviva Aims For Antibiotic Success With La Jolla, Entasis Acquisitions
Having recently bought antibacterial developer Entasis, Innoviva adds approved antibiotic Xerava and hypotension drug Giapreza to its portfolio along with La Jolla’s established commercial organization.
FDA Revokes EUA For Curative Test, Slew Of Other COVID-19 Products
In an ongoing trend, the US agency announced it revoked a number of emergency use authorizations at the behest of manufacturers.
IPO Update: Booming Biopharma On Pace For Another Record Year
Only 25 more initial public offerings are needed for 2021 to beat 2020’s record-breaking 86 IPOs. However, the average return for this year’s offerings is just 1.1% as of 1 July versus 11% at the end of the first quarter.
Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions
During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Palau Pharma S.A.
- TheraLab
- LABOREST Italia S.p.A.
- J. Uriach y Compañía, S.A.
- Uriach OTC, S.L.
- Corporacion J. Uriach, S.A.
- Casa Pronat S.L.